

Table I-5  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Whites

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	477.5	556.7	423.9	190.7	234.7	161.4	65.8	65.5	66.2
Oral Cavity & Pharynx:	10.6	15.7	6.1	2.5	3.8	1.5	61.0	60.2	62.8
Lip	1.0	1.7	0.4	0.0	0.1	0.0	89.7	90.1	87.6
Tongue	2.9	4.3	1.7	0.6	0.9	0.4	59.0	58.7	59.5
Salivary gland	1.2	1.7	0.9	0.2	0.4	0.2	73.9	69.2	80.1
Floor of mouth	0.7	1.1	0.4	0.0	0.1	0.0	53.6	51.7	57.5
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	59.9	56.7	63.5
Nasopharynx	0.4	0.6	0.2	0.2	0.2	0.1	52.9	53.0	51.9
Tonsil	1.5	2.5	0.6	0.2	0.3	0.1	64.2	65.5	58.9
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	40.2	39.0	43.4
Hypopharynx	0.7	1.2	0.3	0.1	0.2	0.0	31.2	31.2	31.1
Other oral cavity & pharynx	0.2	0.4	0.1	0.5	0.8	0.2	34.4	33.9	35.0
Digestive System:	87.0	106.6	71.4	44.1	56.6	34.5	45.8	44.0	48.0
Esophagus	4.6	8.0	1.9	4.3	7.7	1.7	16.6	16.3	17.8
Stomach	7.1	10.2	4.7	3.7	5.2	2.6	22.3	20.6	25.1
Small intestine	1.7	2.1	1.4	0.4	0.4	0.3	57.8	56.7	59.0
Colon & Rectum:	51.2	60.4	44.0	18.9	22.9	15.9	64.9	64.9	64.9
Colon	37.0	42.2	33.0	-	-	-	64.6	64.9	64.4
Rectum	14.2	18.3	11.0	-	-	-	65.6	64.9	66.4
Anus, anal canal & anorectum	1.6	1.3	1.8	0.2	0.2	0.2	68.3	61.2	73.2
Liver & Intrahep:	5.2	7.9	2.9	4.5	6.5	2.8	10.4	9.8	11.7
Liver	4.6	7.2	2.4	3.4	5.3	1.9	11.2	10.2	13.4
Intrahep bile duct	0.6	0.7	0.5	1.1	1.2	0.9	5.9	5.9	5.6
Gallbladder	1.1	0.8	1.4	0.7	0.5	0.8	14.8	12.9	15.4
Other biliary	1.6	2.0	1.3	0.6	0.6	0.5	18.8	20.3	17.0
Pancreas	11.2	12.8	9.9	10.4	12.0	9.0	4.9	5.1	4.7
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	54.1	50.9	57.3
Peritoneum, omentum & mesentery	0.7	0.1	1.2	0.2	0.1	0.4	30.0	38.5	29.4
Other digestive system	0.5	0.5	0.4	0.3	0.4	0.2	7.9	6.4	9.2
Respiratory System:	70.3	88.7	56.7	56.5	75.3	42.8	18.8	18.4	19.3
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	55.8	53.1	59.7
Larynx	3.7	6.5	1.4	1.2	2.2	0.5	64.4	65.4	60.7
Lung & bronchus	65.7	81.0	54.6	55.0	72.6	42.1	15.3	13.2	17.6
Pleura <sup>d</sup>	0.0	0.1	0.0	0.1	0.2	0.0	26.7	27.0	18.9
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	48.0	48.6	46.0
Bones & joints	0.9	1.1	0.8	0.4	0.5	0.4	68.0	64.4	72.5
Soft tissue (incl heart)	3.1	3.7	2.6	1.3	1.5	1.1	66.8	67.4	66.0
Skin (ex basal & squam):	23.4	29.7	18.9	3.9	5.8	2.4	90.5	88.3	93.1
Melanoma of the skin	21.6	27.2	17.6	3.0	4.3	2.0	90.8	88.7	93.3
Other non-epithelial skin	1.8	2.5	1.4	0.9	1.5	0.5	86.1	83.5	89.4
Breast	71.5	1.2	132.5	14.1	0.3	25.0	89.7	86.1	89.7
Breast ( <i>in situ</i> )	16.0	0.1	30.2	-	-	-	100.0	99.7	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-5 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Whites

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.2	-	50.8	9.2	-	16.3	70.7	-	70.7
Cervix uteri	4.3	-	8.5	1.2	-	2.3	72.9	-	72.9
Corpus uteri	12.8	-	23.7	1.1	-	1.9	85.6	-	85.6
Uterus, NOS	0.3	-	0.5	1.2	-	2.0	31.3	-	31.3
Ovary <sup>d</sup>	7.7	-	14.3	5.2	-	9.2	44.6	-	44.6
Vagina	0.4	-	0.7	0.1	-	0.2	52.3	-	52.3
Vulva	1.3	-	2.3	0.3	-	0.5	77.8	-	77.8
Other female genital system	0.4	-	0.7	0.1	-	0.2	63.2	-	63.2
Male Genital System:	75.3	168.8	-	9.8	26.1	-	98.6	98.6	-
Prostate	71.6	161.4	-	9.6	25.6	-	98.9	98.9	-
Testis	3.2	6.3	-	0.1	0.3	-	95.7	95.7	-
Penis	0.4	0.9	-	0.1	0.2	-	68.0	68.0	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	87.3	87.3	-
Urinary System:	37.1	60.1	19.7	9.0	14.4	5.2	74.2	75.6	70.9
Urinary bladder	23.0	40.5	10.1	4.5	7.9	2.3	80.2	81.4	76.6
Kidney & renal pelvis	13.3	18.3	9.1	4.3	6.2	2.8	65.5	65.3	66.0
Ureter	0.6	0.9	0.4	0.1	0.2	0.1	53.2	57.1	47.5
Other urinary system	0.3	0.5	0.1	0.1	0.1	0.1	57.6	61.7	48.9
Eye & Orbit	0.9	1.1	0.8	0.1	0.1	0.1	83.2	83.5	82.9
Brain & Nervous System: <sup>e</sup>	7.0	8.3	5.9	4.8	5.8	3.9	33.2	31.8	35.0
Brain	6.6	7.9	5.5	-	-	-	30.1	29.0	31.6
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	78.6	78.0	78.9
Endocrine System:	9.5	5.4	13.8	0.8	0.8	0.7	94.3	89.1	96.1
Thyroid	8.9	4.6	13.2	0.5	0.5	0.5	97.0	94.3	97.8
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.3	0.3	60.2	61.0	59.0
Lymphoma:	23.1	27.3	19.6	8.4	10.5	6.8	67.5	65.2	70.2
Hodgkin lymphoma	2.9	3.2	2.6	0.5	0.6	0.4	85.3	83.6	87.2
Non-Hodgkin lymphoma	20.2	24.1	17.0	7.9	9.9	6.4	64.1	61.7	66.9
Myeloma	5.2	6.6	4.1	3.5	4.4	2.8	33.4	35.3	31.2
Leukemia:	12.8	16.7	9.9	7.7	10.3	5.8	50.2	50.1	50.2
Lymphocytic:	6.3	8.4	4.6	2.2	3.1	1.6	71.9	71.1	72.9
Acute lymphocytic	1.7	1.9	1.5	0.5	0.6	0.4	64.5	63.1	66.4
Chronic lymphocytic	4.1	5.8	2.9	1.6	2.3	1.1	74.8	73.5	76.8
Other lymphocytic	0.5	0.7	0.2	0.1	0.2	0.1	81.2	83.3	73.8
Myeloid & Monocytic:	5.7	7.2	4.6	3.6	4.7	2.8	28.3	27.2	29.7
Acute myeloid	3.7	4.7	3.1	2.8	3.7	2.3	20.5	19.2	22.0
Chronic myeloid	1.5	2.0	1.2	0.5	0.6	0.4	46.8	45.1	49.3
Acute monocytic	0.3	0.4	0.3	0.0	0.1	0.0	24.3	23.0	25.3
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.2	27.9	26.4	29.5
Other:	0.8	1.0	0.6	1.9	2.5	1.4	18.5	17.3	19.4
Other acute	0.3	0.4	0.3	0.8	1.1	0.7	9.2	5.1	13.0
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	28.8	30.0	26.9
Kaposi Sarcoma <sup>f</sup>	0.6	1.1	0.1	-	-	-	59.2	58.1	76.8
Mesothelioma <sup>f</sup>	1.2	2.3	0.5	-	-	-	8.0	6.5	13.5
Ill-defined & unspecified	10.8	12.3	9.7	14.7	18.5	12.0	15.9	19.4	12.7

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>e</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

<sup>f</sup> Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.